Stem definition | Drug id | CAS RN |
---|---|---|
1497 | 54-85-3 |
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
0.30 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 153 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 7 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 72.92 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.82 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 7.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 29, 1952 | FDA | SANDOZ |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 595.92 | 13.51 | 273 | 18536 | 29275 | 46637978 |
Drug-induced liver injury | 454.35 | 13.51 | 216 | 18593 | 25152 | 46642101 |
Tuberculosis | 400.57 | 13.51 | 152 | 18657 | 10113 | 46657140 |
Paradoxical drug reaction | 380.11 | 13.51 | 103 | 18706 | 2273 | 46664980 |
Acute hepatic failure | 337.82 | 13.51 | 149 | 18660 | 14572 | 46652681 |
Hepatotoxicity | 241.58 | 13.51 | 141 | 18668 | 24868 | 46642385 |
Drug resistance | 236.96 | 13.51 | 123 | 18686 | 17245 | 46650008 |
Hepatitis | 235.50 | 13.51 | 152 | 18657 | 32063 | 46635190 |
Pulmonary tuberculosis | 228.54 | 13.51 | 82 | 18727 | 4649 | 46662604 |
Tuberculoma of central nervous system | 191.85 | 13.51 | 40 | 18769 | 263 | 46666990 |
Jaundice | 188.68 | 13.51 | 127 | 18682 | 28718 | 46638535 |
Disseminated tuberculosis | 164.83 | 13.51 | 56 | 18753 | 2696 | 46664557 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 159.73 | 13.51 | 36 | 18773 | 355 | 46666898 |
Hepatic encephalopathy | 150.28 | 13.51 | 76 | 18733 | 10081 | 46657172 |
Immune reconstitution inflammatory syndrome | 144.47 | 13.51 | 62 | 18747 | 5663 | 46661590 |
Drug interaction | 129.14 | 13.51 | 265 | 18544 | 202829 | 46464424 |
Pyrexia | 126.24 | 13.51 | 366 | 18443 | 348436 | 46318817 |
Liver injury | 113.17 | 13.51 | 74 | 18735 | 15927 | 46651326 |
Transaminases increased | 92.68 | 13.51 | 82 | 18727 | 27679 | 46639574 |
Hepatic failure | 90.82 | 13.51 | 88 | 18721 | 33328 | 46633925 |
Cerebellar ataxia | 89.64 | 13.51 | 27 | 18782 | 877 | 46666376 |
Hepatocellular injury | 86.41 | 13.51 | 81 | 18728 | 29441 | 46637812 |
Hepatic function abnormal | 84.94 | 13.51 | 86 | 18723 | 34335 | 46632918 |
Lymph node tuberculosis | 84.68 | 13.51 | 25 | 18784 | 757 | 46666496 |
Eosinophilia | 83.27 | 13.51 | 66 | 18743 | 19151 | 46648102 |
Alanine aminotransferase increased | 78.05 | 13.51 | 133 | 18676 | 88318 | 46578935 |
Lymphadenopathy | 77.80 | 13.51 | 81 | 18728 | 33407 | 46633846 |
Aspartate aminotransferase increased | 72.97 | 13.51 | 121 | 18688 | 78579 | 46588674 |
Hepatitis fulminant | 70.21 | 13.51 | 32 | 18777 | 3370 | 46663883 |
Tuberculin test positive | 64.35 | 13.51 | 29 | 18780 | 2975 | 46664278 |
Exposure during pregnancy | 61.41 | 13.51 | 135 | 18674 | 108077 | 46559176 |
Encephalopathy | 60.31 | 13.51 | 71 | 18738 | 33518 | 46633735 |
Tuberculosis gastrointestinal | 59.32 | 13.51 | 16 | 18793 | 346 | 46666907 |
Pneumocystis jirovecii pneumonia | 58.94 | 13.51 | 49 | 18760 | 15199 | 46652054 |
Loss of employment | 57.76 | 13.51 | 21 | 18788 | 1235 | 46666018 |
Peritoneal tuberculosis | 56.92 | 13.51 | 17 | 18792 | 536 | 46666717 |
Mycobacterium tuberculosis complex test positive | 56.62 | 13.51 | 22 | 18787 | 1556 | 46665697 |
Meningitis tuberculous | 56.15 | 13.51 | 17 | 18792 | 562 | 46666691 |
Tuberculosis of central nervous system | 54.05 | 13.51 | 15 | 18794 | 362 | 46666891 |
Latent tuberculosis | 52 | 13.51 | 22 | 18787 | 1938 | 46665315 |
Pain | 47.92 | 13.51 | 74 | 18735 | 476874 | 46190379 |
Liver transplant | 47.57 | 13.51 | 22 | 18787 | 2395 | 46664858 |
Generalised tonic-clonic seizure | 46.49 | 13.51 | 56 | 18753 | 27066 | 46640187 |
Liver disorder | 43.90 | 13.51 | 64 | 18745 | 37182 | 46630071 |
Fatigue | 43.60 | 13.51 | 115 | 18694 | 608582 | 46058671 |
Glomerulonephritis minimal lesion | 43.55 | 13.51 | 11 | 18798 | 182 | 46667071 |
Rash maculo-papular | 38.97 | 13.51 | 52 | 18757 | 27822 | 46639431 |
Hepatitis toxic | 37.34 | 13.51 | 20 | 18789 | 2980 | 46664273 |
Fall | 37.04 | 13.51 | 47 | 18762 | 329050 | 46338203 |
Product dose omission issue | 35.18 | 13.51 | 12 | 18797 | 168508 | 46498745 |
Coagulopathy | 33.02 | 13.51 | 39 | 18770 | 18460 | 46648793 |
Focal dyscognitive seizures | 32.83 | 13.51 | 18 | 18791 | 2810 | 46664443 |
Hepatic necrosis | 32.67 | 13.51 | 23 | 18786 | 5578 | 46661675 |
Hepatosplenomegaly | 32.64 | 13.51 | 17 | 18792 | 2393 | 46664860 |
Serpiginous choroiditis | 32.59 | 13.51 | 6 | 18803 | 18 | 46667235 |
Bovine tuberculosis | 32.15 | 13.51 | 7 | 18802 | 58 | 46667195 |
Hepatic haematoma | 30.73 | 13.51 | 10 | 18799 | 420 | 46666833 |
Tuberculous pleurisy | 30.42 | 13.51 | 10 | 18799 | 434 | 46666819 |
Choroiditis | 30.39 | 13.51 | 8 | 18801 | 157 | 46667096 |
Myocarditis | 30.17 | 13.51 | 25 | 18784 | 7714 | 46659539 |
Hypertransaminasaemia | 29.32 | 13.51 | 18 | 18791 | 3470 | 46663783 |
Serotonin syndrome | 29.09 | 13.51 | 42 | 18767 | 24178 | 46643075 |
Face oedema | 28.74 | 13.51 | 37 | 18772 | 19116 | 46648137 |
C-reactive protein increased | 26.55 | 13.51 | 67 | 18742 | 58523 | 46608730 |
Multiple-drug resistance | 26.17 | 13.51 | 15 | 18794 | 2550 | 46664703 |
Hemianopia heteronymous | 26.11 | 13.51 | 6 | 18803 | 65 | 46667188 |
Immune system disorder | 25.45 | 13.51 | 23 | 18786 | 7972 | 46659281 |
Jarisch-Herxheimer reaction | 25.35 | 13.51 | 8 | 18801 | 304 | 46666949 |
Drug level decreased | 24.95 | 13.51 | 20 | 18789 | 5892 | 46661361 |
Neurotoxicity | 24.62 | 13.51 | 29 | 18780 | 13688 | 46653565 |
Aspergillus infection | 24.28 | 13.51 | 21 | 18788 | 6869 | 46660384 |
Liver function test abnormal | 24.10 | 13.51 | 56 | 18753 | 46431 | 46620822 |
Lupus-like syndrome | 23.86 | 13.51 | 22 | 18787 | 7822 | 46659431 |
Ocular icterus | 23.71 | 13.51 | 16 | 18793 | 3624 | 46663629 |
Microcytic anaemia | 23.55 | 13.51 | 15 | 18794 | 3083 | 46664170 |
Hepatic enzyme increased | 23.09 | 13.51 | 79 | 18730 | 81708 | 46585545 |
Interstitial lung disease | 22.70 | 13.51 | 60 | 18749 | 53889 | 46613364 |
Trichophytosis | 22.30 | 13.51 | 5 | 18804 | 48 | 46667205 |
Death | 21.99 | 13.51 | 66 | 18743 | 335482 | 46331771 |
Anxiety | 21.48 | 13.51 | 25 | 18784 | 181932 | 46485321 |
Pericarditis tuberculous | 21.04 | 13.51 | 4 | 18805 | 15 | 46667238 |
Gamma-glutamyltransferase increased | 20.76 | 13.51 | 42 | 18767 | 31698 | 46635555 |
Hepatitis B core antibody positive | 20.57 | 13.51 | 6 | 18803 | 174 | 46667079 |
Pleural effusion | 19.91 | 13.51 | 76 | 18733 | 82876 | 46584377 |
Hyperinsulinaemia | 19.90 | 13.51 | 5 | 18804 | 81 | 46667172 |
Feeling abnormal | 19.81 | 13.51 | 13 | 18796 | 125047 | 46542206 |
Blood bilirubin increased | 19.75 | 13.51 | 43 | 18766 | 34141 | 46633112 |
Central venous pressure increased | 19.62 | 13.51 | 5 | 18804 | 86 | 46667167 |
Liver transplant rejection | 19.43 | 13.51 | 10 | 18799 | 1373 | 46665880 |
Diarrhoea | 19.43 | 13.51 | 139 | 18670 | 559463 | 46107790 |
Nephrotic syndrome | 19.40 | 13.51 | 16 | 18793 | 4905 | 46662348 |
Muscle spasms | 19.23 | 13.51 | 13 | 18796 | 123100 | 46544153 |
Rash morbilliform | 19.06 | 13.51 | 13 | 18796 | 2996 | 46664257 |
Vomiting | 18.89 | 13.51 | 271 | 18538 | 452523 | 46214730 |
Blood beta-D-glucan increased | 18.65 | 13.51 | 6 | 18803 | 243 | 46667010 |
Granuloma | 18.53 | 13.51 | 14 | 18795 | 3784 | 46663469 |
Lymphadenitis | 18.29 | 13.51 | 12 | 18797 | 2593 | 46664660 |
Joint tuberculosis | 18.28 | 13.51 | 5 | 18804 | 114 | 46667139 |
Substance-induced psychotic disorder | 18.24 | 13.51 | 10 | 18799 | 1560 | 46665693 |
Cerebrovascular accident | 18.15 | 13.51 | 9 | 18800 | 101030 | 46566223 |
Mycobacterial infection | 17.87 | 13.51 | 10 | 18799 | 1623 | 46665630 |
Pneumonia lipoid | 17.59 | 13.51 | 5 | 18804 | 132 | 46667121 |
Stillbirth | 17.44 | 13.51 | 17 | 18792 | 6474 | 46660779 |
Hepatic steatosis | 17.15 | 13.51 | 33 | 18776 | 24009 | 46643244 |
Optic neuropathy | 16.99 | 13.51 | 10 | 18799 | 1786 | 46665467 |
Cytomegalovirus infection | 16.93 | 13.51 | 28 | 18781 | 18116 | 46649137 |
Immunosuppressant drug level decreased | 16.85 | 13.51 | 8 | 18801 | 924 | 46666329 |
Toxic optic neuropathy | 16.82 | 13.51 | 5 | 18804 | 155 | 46667098 |
Acute respiratory distress syndrome | 16.77 | 13.51 | 31 | 18778 | 21891 | 46645362 |
Drug level increased | 16.59 | 13.51 | 28 | 18781 | 18413 | 46648840 |
Chromaturia | 16.53 | 13.51 | 25 | 18784 | 14994 | 46652259 |
Pathogen resistance | 16.53 | 13.51 | 16 | 18793 | 6044 | 46661209 |
Constipation | 16.48 | 13.51 | 28 | 18781 | 174069 | 46493184 |
Depression | 16.43 | 13.51 | 27 | 18782 | 170077 | 46497176 |
Hepatic cyst | 15.74 | 13.51 | 14 | 18795 | 4752 | 46662501 |
Mycobacterium avium complex infection | 15.74 | 13.51 | 11 | 18798 | 2637 | 46664616 |
Cholestatic liver injury | 15.59 | 13.51 | 10 | 18799 | 2080 | 46665173 |
Bilirubin conjugated increased | 15.55 | 13.51 | 11 | 18798 | 2687 | 46664566 |
Organising pneumonia | 15.40 | 13.51 | 14 | 18795 | 4888 | 46662365 |
Drug hypersensitivity | 15.22 | 13.51 | 49 | 18760 | 243776 | 46423477 |
Transplant rejection | 15.12 | 13.51 | 19 | 18790 | 9577 | 46657676 |
Liver palpable | 14.92 | 13.51 | 3 | 18806 | 16 | 46667237 |
Optic neuritis | 14.84 | 13.51 | 16 | 18793 | 6855 | 46660398 |
Granulomatous dermatitis | 14.24 | 13.51 | 4 | 18805 | 101 | 46667152 |
Completed suicide | 14.24 | 13.51 | 23 | 18786 | 145897 | 46521356 |
Sinusitis | 14.08 | 13.51 | 19 | 18790 | 129749 | 46537504 |
Contusion | 13.98 | 13.51 | 9 | 18800 | 87478 | 46579775 |
Hyperuricaemia | 13.90 | 13.51 | 13 | 18796 | 4704 | 46662549 |
Toxoplasmosis | 13.81 | 13.51 | 8 | 18801 | 1386 | 46665867 |
Antipsychotic drug level above therapeutic | 13.79 | 13.51 | 7 | 18802 | 934 | 46666319 |
Encephalitis | 13.79 | 13.51 | 16 | 18793 | 7432 | 46659821 |
Paraparesis | 13.78 | 13.51 | 9 | 18800 | 1930 | 46665323 |
Memory impairment | 13.72 | 13.51 | 7 | 18802 | 77330 | 46589923 |
Status epilepticus | 13.62 | 13.51 | 22 | 18787 | 13957 | 46653296 |
Mycoplasma genitalium infection | 13.56 | 13.51 | 3 | 18806 | 27 | 46667226 |
Central nervous system immune reconstitution inflammatory response | 13.56 | 13.51 | 3 | 18806 | 27 | 46667226 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Paradoxical drug reaction | 787.91 | 13.79 | 205 | 18217 | 2457 | 29931599 |
Tuberculosis | 461.23 | 13.79 | 177 | 18245 | 7900 | 29926156 |
Drug-induced liver injury | 406.66 | 13.79 | 217 | 18205 | 21057 | 29912999 |
Drug reaction with eosinophilia and systemic symptoms | 388.70 | 13.79 | 233 | 18189 | 28255 | 29905801 |
Immune reconstitution inflammatory syndrome | 365.98 | 13.79 | 155 | 18267 | 8946 | 29925110 |
Hepatotoxicity | 326.88 | 13.79 | 178 | 18244 | 17967 | 29916089 |
Jaundice | 293.21 | 13.79 | 205 | 18217 | 32281 | 29901775 |
Pulmonary tuberculosis | 275.60 | 13.79 | 106 | 18316 | 4751 | 29929305 |
Drug resistance | 219.70 | 13.79 | 143 | 18279 | 19990 | 29914066 |
Hepatitis | 187.52 | 13.79 | 135 | 18287 | 22221 | 29911835 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 181.85 | 13.79 | 44 | 18378 | 381 | 29933675 |
Tuberculoma of central nervous system | 176.05 | 13.79 | 40 | 18382 | 255 | 29933801 |
Disseminated tuberculosis | 145.18 | 13.79 | 53 | 18369 | 2049 | 29932007 |
Meningitis tuberculous | 117.64 | 13.79 | 33 | 18389 | 532 | 29933524 |
Pyrexia | 92.22 | 13.79 | 391 | 18031 | 294098 | 29639958 |
Immune system disorder | 91.18 | 13.79 | 47 | 18375 | 4230 | 29929826 |
Acute hepatic failure | 89.14 | 13.79 | 67 | 18355 | 11760 | 29922296 |
Serpiginous choroiditis | 75.83 | 13.79 | 16 | 18406 | 68 | 29933988 |
Drug interaction | 74.34 | 13.79 | 280 | 18142 | 199288 | 29734768 |
Latent tuberculosis | 69.90 | 13.79 | 25 | 18397 | 910 | 29933146 |
Alanine aminotransferase increased | 69.59 | 13.79 | 146 | 18276 | 74130 | 29859926 |
Lymph node tuberculosis | 68.95 | 13.79 | 21 | 18401 | 457 | 29933599 |
Death | 68.00 | 13.79 | 72 | 18350 | 357211 | 29576845 |
Optic neuritis | 64.53 | 13.79 | 34 | 18388 | 3200 | 29930856 |
Hepatic function abnormal | 64.17 | 13.79 | 102 | 18320 | 41843 | 29892213 |
Tuberculosis of central nervous system | 63.69 | 13.79 | 16 | 18406 | 164 | 29933892 |
Granuloma | 61.95 | 13.79 | 30 | 18392 | 2362 | 29931694 |
Hepatitis toxic | 59.49 | 13.79 | 28 | 18394 | 2069 | 29931987 |
Hepatic failure | 59.41 | 13.79 | 88 | 18334 | 33955 | 29900101 |
Lymphadenopathy | 57.64 | 13.79 | 73 | 18349 | 24303 | 29909753 |
Liver function test abnormal | 56.90 | 13.79 | 82 | 18340 | 30868 | 29903188 |
Fall | 55.96 | 13.79 | 21 | 18401 | 181851 | 29752205 |
Hepatic enzyme increased | 54.77 | 13.79 | 84 | 18338 | 33410 | 29900646 |
Bone tuberculosis | 54.18 | 13.79 | 16 | 18406 | 312 | 29933744 |
Hepatitis fulminant | 50.45 | 13.79 | 31 | 18391 | 3910 | 29930146 |
Tubulointerstitial nephritis | 49.47 | 13.79 | 58 | 18364 | 17833 | 29916223 |
Aspartate aminotransferase increased | 48.50 | 13.79 | 115 | 18307 | 63307 | 29870749 |
Hydrocephalus | 48.39 | 13.79 | 31 | 18391 | 4206 | 29929850 |
Tuberculous pleurisy | 47.70 | 13.79 | 15 | 18407 | 364 | 29933692 |
Skin disorder | 46.88 | 13.79 | 46 | 18376 | 11562 | 29922494 |
Tuberculosis gastrointestinal | 41.75 | 13.79 | 12 | 18410 | 212 | 29933844 |
Transaminases increased | 41.43 | 13.79 | 61 | 18361 | 23396 | 29910660 |
Demodicidosis | 41.33 | 13.79 | 11 | 18411 | 144 | 29933912 |
Optic neuropathy | 40.66 | 13.79 | 20 | 18402 | 1629 | 29932427 |
Tuberculosis of eye | 39.37 | 13.79 | 8 | 18414 | 27 | 29934029 |
Peritoneal tuberculosis | 38.70 | 13.79 | 13 | 18409 | 391 | 29933665 |
Mycobacterium tuberculosis complex test positive | 37.37 | 13.79 | 16 | 18406 | 945 | 29933111 |
Tuberculin test positive | 36.90 | 13.79 | 16 | 18406 | 975 | 29933081 |
Granulomatous liver disease | 35.84 | 13.79 | 13 | 18409 | 493 | 29933563 |
Drug level decreased | 35.33 | 13.79 | 29 | 18393 | 5776 | 29928280 |
Hepatocellular injury | 34.95 | 13.79 | 59 | 18363 | 25412 | 29908644 |
Bovine tuberculosis | 33.26 | 13.79 | 9 | 18413 | 126 | 29933930 |
Type III immune complex mediated reaction | 31.83 | 13.79 | 10 | 18412 | 242 | 29933814 |
Drug eruption | 31.56 | 13.79 | 46 | 18376 | 17480 | 29916576 |
Eosinophilia | 31.30 | 13.79 | 52 | 18370 | 22108 | 29911948 |
Optic atrophy | 30.44 | 13.79 | 13 | 18409 | 763 | 29933293 |
Disseminated Bacillus Calmette-Guerin infection | 30.04 | 13.79 | 8 | 18414 | 105 | 29933951 |
Liver disorder | 29.64 | 13.79 | 60 | 18362 | 29662 | 29904394 |
Toxic epidermal necrolysis | 29.32 | 13.79 | 45 | 18377 | 17895 | 29916161 |
Colour blindness | 28.60 | 13.79 | 9 | 18413 | 219 | 29933837 |
Myocardial infarction | 27.71 | 13.79 | 22 | 18400 | 125603 | 29808453 |
Liver injury | 27.52 | 13.79 | 36 | 18386 | 12364 | 29921692 |
Blood bilirubin increased | 27.51 | 13.79 | 66 | 18356 | 36570 | 29897486 |
Completed suicide | 26.60 | 13.79 | 14 | 18408 | 99478 | 29834578 |
Condition aggravated | 26.54 | 13.79 | 160 | 18262 | 137706 | 29796350 |
Atrial fibrillation | 26.38 | 13.79 | 17 | 18405 | 108107 | 29825949 |
Splenic abscess | 26.06 | 13.79 | 9 | 18413 | 295 | 29933761 |
Hyperuricaemia | 25.66 | 13.79 | 27 | 18395 | 7367 | 29926689 |
Lichenoid keratosis | 25.61 | 13.79 | 16 | 18406 | 2078 | 29931978 |
Extrapulmonary tuberculosis | 25.36 | 13.79 | 7 | 18415 | 106 | 29933950 |
Mycobacterium fortuitum infection | 25.33 | 13.79 | 8 | 18414 | 197 | 29933859 |
Diarrhoea | 25.15 | 13.79 | 113 | 18309 | 333990 | 29600066 |
Cholestasis | 24.44 | 13.79 | 50 | 18372 | 24900 | 29909156 |
Pain | 24.42 | 13.79 | 43 | 18379 | 172598 | 29761458 |
Product dose omission issue | 24.34 | 13.79 | 13 | 18409 | 91618 | 29842438 |
Papilloma | 24.33 | 13.79 | 7 | 18415 | 124 | 29933932 |
Hepatic encephalopathy | 23.76 | 13.79 | 36 | 18386 | 14156 | 29919900 |
Bilirubin conjugated increased | 23.08 | 13.79 | 18 | 18404 | 3333 | 29930723 |
Multiple-drug resistance | 22.90 | 13.79 | 17 | 18405 | 2924 | 29931132 |
Oral candidiasis | 22.81 | 13.79 | 31 | 18391 | 11040 | 29923016 |
Rash maculo-papular | 22.64 | 13.79 | 49 | 18373 | 25369 | 29908687 |
Hypotension | 22.47 | 13.79 | 57 | 18365 | 200508 | 29733548 |
Dermatitis exfoliative | 22.00 | 13.79 | 25 | 18397 | 7431 | 29926625 |
Papule | 21.95 | 13.79 | 17 | 18405 | 3116 | 29930940 |
Ocular toxicity | 21.84 | 13.79 | 7 | 18415 | 181 | 29933875 |
Pericarditis tuberculous | 21.20 | 13.79 | 6 | 18416 | 100 | 29933956 |
Diaphragmatic injury | 21.12 | 13.79 | 5 | 18417 | 39 | 29934017 |
Malignant neoplasm progression | 21.12 | 13.79 | 9 | 18413 | 72278 | 29861778 |
Erythrodermic psoriasis | 21.08 | 13.79 | 10 | 18412 | 752 | 29933304 |
Tuberculosis of genitourinary system | 20.90 | 13.79 | 5 | 18417 | 41 | 29934015 |
Hepatic necrosis | 20.83 | 13.79 | 18 | 18404 | 3845 | 29930211 |
Mycobacterial infection | 20.67 | 13.79 | 13 | 18409 | 1708 | 29932348 |
Transient aphasia | 20.46 | 13.79 | 6 | 18416 | 114 | 29933942 |
Red man syndrome | 20.24 | 13.79 | 10 | 18412 | 822 | 29933234 |
Unmasking of previously unidentified disease | 20.15 | 13.79 | 9 | 18413 | 589 | 29933467 |
Central nervous system vasculitis | 20.12 | 13.79 | 8 | 18414 | 391 | 29933665 |
Liver transplant rejection | 20.08 | 13.79 | 14 | 18408 | 2184 | 29931872 |
Encephalopathy | 20.00 | 13.79 | 54 | 18368 | 32151 | 29901905 |
Complications of transplanted kidney | 19.90 | 13.79 | 18 | 18404 | 4083 | 29929973 |
Tuberculoid leprosy | 19.84 | 13.79 | 5 | 18417 | 52 | 29934004 |
Chronic allograft nephropathy | 19.75 | 13.79 | 11 | 18411 | 1155 | 29932901 |
Cardiac failure congestive | 19.61 | 13.79 | 14 | 18408 | 84393 | 29849663 |
Mitochondrial neurogastrointestinal encephalopathy | 19.57 | 13.79 | 4 | 18418 | 14 | 29934042 |
Dilatation intrahepatic duct acquired | 19.50 | 13.79 | 5 | 18417 | 56 | 29934000 |
Pulmonary sequestration | 19.42 | 13.79 | 5 | 18417 | 57 | 29933999 |
Thalamic infarction | 19.42 | 13.79 | 9 | 18413 | 642 | 29933414 |
Tuberculosis liver | 19.04 | 13.79 | 5 | 18417 | 62 | 29933994 |
Constipation | 18.96 | 13.79 | 25 | 18397 | 112881 | 29821175 |
Trisomy 21 | 18.90 | 13.79 | 8 | 18414 | 459 | 29933597 |
Anaplastic astrocytoma | 18.58 | 13.79 | 6 | 18416 | 159 | 29933897 |
Feeling abnormal | 18.36 | 13.79 | 6 | 18416 | 56750 | 29877306 |
Dyspnoea | 18.33 | 13.79 | 125 | 18297 | 333170 | 29600886 |
Granulomatous lymphadenitis | 18.28 | 13.79 | 5 | 18417 | 73 | 29933983 |
Ototoxicity | 17.92 | 13.79 | 11 | 18411 | 1385 | 29932671 |
Cryptococcosis | 17.70 | 13.79 | 12 | 18410 | 1790 | 29932266 |
Cachexia | 17.55 | 13.79 | 21 | 18401 | 6590 | 29927466 |
Fatigue | 17.27 | 13.79 | 121 | 18301 | 320552 | 29613504 |
Liver transplant | 17.06 | 13.79 | 14 | 18408 | 2788 | 29931268 |
Psoas abscess | 16.98 | 13.79 | 8 | 18414 | 592 | 29933464 |
Hemianopia heteronymous | 16.59 | 13.79 | 4 | 18418 | 34 | 29934022 |
Genitourinary tract infection | 16.58 | 13.79 | 5 | 18417 | 105 | 29933951 |
Coronary artery disease | 16.54 | 13.79 | 5 | 18417 | 49707 | 29884349 |
Past-pointing | 16.49 | 13.79 | 4 | 18418 | 35 | 29934021 |
Protrusion tongue | 16.45 | 13.79 | 6 | 18416 | 231 | 29933825 |
Pneumocystis jirovecii pneumonia | 16.40 | 13.79 | 34 | 18388 | 17086 | 29916970 |
Spermatozoa progressive motility abnormal | 16.20 | 13.79 | 4 | 18418 | 38 | 29934018 |
Testicular mass | 15.87 | 13.79 | 5 | 18417 | 122 | 29933934 |
Herpes zoster meningoencephalitis | 15.78 | 13.79 | 6 | 18416 | 260 | 29933796 |
Leprosy | 15.68 | 13.79 | 5 | 18417 | 127 | 29933929 |
Spermatozoa progressive motility decreased | 15.43 | 13.79 | 5 | 18417 | 134 | 29933922 |
Urogenital infection bacterial | 15.35 | 13.79 | 4 | 18418 | 48 | 29934008 |
Insomnia | 15.32 | 13.79 | 21 | 18401 | 93315 | 29840741 |
Myxoedema coma | 15.12 | 13.79 | 6 | 18416 | 292 | 29933764 |
Cell death | 15.02 | 13.79 | 12 | 18410 | 2299 | 29931757 |
Vaccination failure | 14.86 | 13.79 | 5 | 18417 | 151 | 29933905 |
Encephalitis | 14.77 | 13.79 | 19 | 18403 | 6417 | 29927639 |
Chronic obstructive pulmonary disease | 14.71 | 13.79 | 5 | 18417 | 46121 | 29887935 |
Vasculitis | 14.42 | 13.79 | 21 | 18401 | 7969 | 29926087 |
Chorioretinitis | 14.30 | 13.79 | 5 | 18417 | 170 | 29933886 |
Hypermetabolism | 14.30 | 13.79 | 5 | 18417 | 170 | 29933886 |
Cardiac arrest | 14.16 | 13.79 | 22 | 18400 | 92828 | 29841228 |
Mycobacterium abscessus infection | 14.10 | 13.79 | 7 | 18415 | 581 | 29933475 |
Face oedema | 13.91 | 13.79 | 25 | 18397 | 11309 | 29922747 |
Source | Code | Description |
---|---|---|
ATC | J04AC01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Hydrazides |
ATC | J04AC51 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Hydrazides |
ATC | J04AM01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
ATC | J04AM02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
ATC | J04AM03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
ATC | J04AM04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
ATC | J04AM05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
ATC | J04AM06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
ATC | J04AM07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
ATC | J04AM08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
FDA EPC | N0000175483 | Antimycobacterial |
CHEBI has role | CHEBI:33231 | antitubercular |
CHEBI has role | CHEBI:88188 | allergenic drug |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000995 | Antitubercular Agents |
MeSH PA | D054872 | Fatty Acid Synthesis Inhibitors |
MeSH PA | D000960 | Hypolipidemic Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Inactive tuberculosis | indication | 11999007 | |
Acute tuberculosis | indication | 25629007 | |
Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
Tuberculosis of meninges | off-label use | 58437007 | |
Atypical mycobacterial infection | off-label use | 111812000 | |
Nutritional disorder | contraindication | 2492009 | DOID:374 |
Alcoholism | contraindication | 7200002 | |
Jaundice | contraindication | 18165001 | |
Acute hepatitis | contraindication | 37871000 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Gout | contraindication | 90560007 | DOID:13189 |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Acute hepatic failure | contraindication | 197270009 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Diabetic - poor control | contraindication | 268519009 | |
Peripheral nerve disease | contraindication | 302226006 | |
Porphyria | contraindication | 418470004 | |
Diabetic peripheral neuropathy | contraindication | 424736006 | |
Slow acetylator due to N-acetyltransferase enzyme variant | contraindication | 425079005 | |
Prolonged-Severe Nausea and Vomiting | contraindication | ||
Chronic Hepatic Disease | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.98 | acidic |
pKa2 | 3.79 | Basic |
pKa3 | 1.94 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Cytochrome P450 3A4 | Enzyme | IC50 | 5.31 | WOMBAT-PK | |||||
Cytochrome P450 3A5 | Enzyme | IC50 | 4.96 | WOMBAT-PK | |||||
Enoyl-[acyl-carrier-protein] reductase [NADH] | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
Catalase-peroxidase | Enzyme | WOMBAT-PK | |||||||
Dihydrofolate reductase | Enzyme | Ki | 9 | CHEMBL |
ID | Source |
---|---|
4017505 | VUID |
N0000145890 | NUI |
D00346 | KEGG_DRUG |
4017505 | VANDF |
C0022209 | UMLSCUI |
CHEBI:6030 | CHEBI |
NIZ | PDB_CHEM_ID |
3767 | PUBCHEM_CID |
CHEMBL64 | ChEMBL_ID |
DB00951 | DRUGBANK_ID |
D007538 | MESH_DESCRIPTOR_UI |
4188 | INN_ID |
V83O1VOZ8L | UNII |
6038 | RXNORM |
2955 | MMSL |
4929 | MMSL |
d00101 | MMSL |
002844 | NDDF |
387472004 | SNOMEDCT_US |
81335000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1655 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-7655 | TABLET | 300 mg | ORAL | ANDA | 22 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1109 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0066 | TABLET | 100 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0071 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3056 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 25 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-584 | TABLET | 300 mg | ORAL | ANDA | 22 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-087 | TABLET | 300 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-121 | TABLET | 300 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-218 | TABLET | 300 mg | ORAL | ANDA | 22 sections |
ISONIAZID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-984 | TABLET | 300 mg | ORAL | ANDA | 13 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-627 | TABLET | 300 mg | ORAL | ANDA | 22 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-463 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 46287-009 | SOLUTION | 50 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0370 | TABLET | 300 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0370 | TABLET | 300 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0410 | TABLET | 100 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1490 | SOLUTION | 50 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-083 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-391 | TABLET | 300 mg | ORAL | ANDA | 10 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52959-145 | TABLET | 300 mg | ORAL | ANDA | 22 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-2920 | TABLET | 300 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-1041 | TABLET | 300 mg | ORAL | ANDA | 23 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2304 | TABLET | 100 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2416 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55695-027 | TABLET | 100 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55695-031 | SOLUTION | 50 mg | ORAL | ANDA | 25 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55695-033 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-553 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Isoniazid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61748-013 | TABLET | 300 mg | ORAL | ANDA | 23 sections |